46 results on '"Camastra C"'
Search Results
2. OC.09.5 LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN’S DISEASE: A MULTICENTER REALLIFE STUDY
- Author
-
Scribano, M.L., primary, Aratari, A., additional, Neri, B., additional, Bezzio, C., additional, Balestrieri, P., additional, Falasco, G., additional, Camastra, C., additional, Pantanella, P., additional, Monterubbianesi, R., additional, Tullio, A., additional, Saibeni, S., additional, Papi, C., additional, Biancone, L., additional, Cosintino, R., additional, and Faggiani, R., additional
- Published
- 2021
- Full Text
- View/download PDF
3. P327 Long-term effectiveness of ustekinumab in refractory Crohn’s disease: an Italian multicenter real-life study
- Author
-
Scribano, M L, primary, Aratari, A, additional, Neri, B, additional, Bezzio, C, additional, Balestrieri, P, additional, Falasco, G, additional, Camastra, C, additional, Pantanella, P, additional, Monterubbianesi, R, additional, Tullio, A, additional, Saibeni, S, additional, Papi, C, additional, Biancone, L, additional, Cosintino, R, additional, and Faggiani, R, additional
- Published
- 2021
- Full Text
- View/download PDF
4. A case of intravascular large B cell lymphoma: New clinical and immunohistochemical findings
- Author
-
MANSUETO, GELSOMINA, DE ROSA, GAETANO, Di Vito, A, Belluomo, C, Murino, P, Natella, V, Camastra, C, Presta, I, Malara, N, Donato, G, Mignogna, C., Mansueto, Gelsomina, Di Vito, A, Belluomo, C, Murino, P, Natella, V, Camastra, C, Presta, I, Malara, N, DE ROSA, Gaetano, Donato, G, and Mignogna, C.
- Subjects
Galectin 3 ,Hachinski ,Immunohistochemistry ,IVLBCL ,Vascular dementia - Abstract
Intravascular large B cell lymphoma (IVLBCL) is a rare extranodal non-Hodgkin lymphoma characterized by proliferation of malignant cells within the lumen of small vessels, with a predilection for the CNS and the skin. IVLBCL clinical course is highly aggressive, clinical signs and symptoms are not specific and may consist of neurological and cognitive impairment, fever of unknown origin and cutaneous lesions, lacking of a typical neuroimaging pattern. For all these reasons the diagnosis is commonly missed and the exitus is frequent, therefore post mortem evaluation is necessary to clarify the clinical history. We present a case of IVLBCL in a 62-year-old woman with unusual symptomatology, mimicking a vascular, multi-infarctual cerebropathy. Hachinski Ischemic Score was 7 suggesting a vascular dementia. Autopsy was unable to define the nature of the disease. Immunohistochemical analysis for cluster of differentiation 20 (CD20) revealed the ubiquitous presence of malignant lymphoid B-cells into the vessel of all organs analyzed, allowing the definitive diagnosis of IVLBCL. The atypical cells expressed high levels of anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Galectin-3, and showed cellular myelocytomatosis (c-Myc) staining in
- Published
- 2016
5. Innate immunity in cutaneous melanoma
- Author
-
Mignogna, C., primary, Scali, E., additional, Camastra, C., additional, Presta, I., additional, Zeppa, P., additional, Barni, T., additional, Donato, G., additional, Bottoni, U., additional, and Di Vito, A., additional
- Published
- 2017
- Full Text
- View/download PDF
6. Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide: report of two cases
- Author
-
Malara, N., primary, Guzzi, G., additional, Mignogna, C., additional, Trunzo, V., additional, Camastra, C., additional, Torre, A. Della, additional, Di Vito, A., additional, Lavecchia, A. M., additional, Gliozzi, M., additional, Ceccotti, C., additional, Volpentesta, G., additional, Lavano, A., additional, Donato, G., additional, and Mollace, V, additional
- Published
- 2016
- Full Text
- View/download PDF
7. Elastofibroma dorsi: a histochemical and immunohistochemical study
- Author
-
Di Vito, A., primary, Scali, E., additional, Ferraro, G., additional, Mignogna, C., additional, Presta, I., additional, Camastra, C., additional, Palmieri, C., additional, Donato, G., additional, and Barni, T., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Macrophage Activation and Patterns of Inflammation in Obese and Non-Obese Women with Breast Carcinoma
- Author
-
Renne, M., primary, Conforti, F., additional, Camastra, C., additional, Donato, A., additional, and Donato, G., additional
- Published
- 2014
- Full Text
- View/download PDF
9. Clinical nephrology - miscellaneous
- Author
-
Bantis, C., primary, Heering, P., additional, Kouri, N.-M., additional, Siekierka-Harreis, M., additional, Stangou, M., additional, Schwandt, C., additional, Efstratiadis, G., additional, Rump, L.-C., additional, Ivens, K., additional, Haddiya, I., additional, Houssaini Squalli, T., additional, Laouad, I., additional, Ramdani, B., additional, Bayahia, R., additional, Dimas, G. G., additional, Tegos, T. J., additional, Spiroglou, S. G., additional, Pitsalidis, C. G., additional, Sioulis, A. S., additional, Karamouzis, I. M., additional, Savopoulos, C. G., additional, Karamouzis, M. I., additional, Orologas, A. G., additional, Hatzitolios, A. I., additional, Grekas, D. M., additional, Maixnerova, D., additional, Jancova, E., additional, Rychlik, I., additional, Rysava, R., additional, Merta, M., additional, Reiterova, J., additional, Kolsky, A., additional, Honsova, E., additional, Skibova, J., additional, Tesar, V., additional, Kendi Celebi, Z., additional, Calayoglu, R., additional, Keven, K., additional, Kurultak, I., additional, Mescigil, P., additional, Erbay, B., additional, Karatan, O., additional, Duman, N., additional, Erturk, S., additional, Nergizoglu, G., additional, Kutlay, S., additional, Sengul, S., additional, Ates, K., additional, Marino, F., additional, Martorano, C., additional, Bellantoni, M., additional, Tripepi, R., additional, Zoccali, C., additional, Ishizuka, K., additional, Harita, Y., additional, Kajiho, Y., additional, Tsurumi, H., additional, Asano, T., additional, Nishiyama, K., additional, Sugawara, N., additional, Chikamoto, H., additional, Akioka, Y., additional, Yamaguchi, Y., additional, Igarashi, T., additional, Hattori, M., additional, Bantis, C., additional, Heering, P. J., additional, Sahay, M., additional, Monova, D. V., additional, Monov, S. V., additional, Wang, Y.-y., additional, Cheng, H., additional, Wang, G.-q., additional, Dong, H.-r., additional, Chen, Y.-p., additional, Wang, C.-j., additional, Tang, Y.-l., additional, Buti, E., additional, Dervishi, E., additional, Bergesio, F., additional, Ghiandai, G., additional, Mjeshtri, A., additional, Paudice, N., additional, Caldini, A. L., additional, Nozzoli, C., additional, Minetti, E. E., additional, Sun, L., additional, Feng, J., additional, Yao, L., additional, Fan, Q., additional, Ma, J., additional, Wang, L., additional, Kirsanova, T., additional, Merkusheva, L., additional, Ruinihina, N., additional, Kozlovskaya, N., additional, Elenshleger, G., additional, Turgutalp, K., additional, Karabulut, U., additional, Ozcan, T., additional, Helvaci, I., additional, Kiykim, A., additional, Kaul, A., additional, Bhadhuaria, D., additional, sharma, R., additional, Prasad, N., additional, Gupta, A., additional, Clajus, C., additional, Schmidt, J., additional, Haller, H., additional, Kumpers, P., additional, David, S., additional, Sevillano, A. M., additional, Molina, M., additional, Gutierrez, E., additional, Morales, E., additional, Gonzalez, E., additional, Hernandez, E., additional, Praga, M., additional, Conde Olasagasti, J. L., additional, Vozmediano Poyatos, C., additional, Illescas, M. L., additional, Tallon, S., additional, Uson Carrasco, J. J., additional, Roca Munoz, A., additional, Rivera Hernandez, F., additional, Ismail, G., additional, Jurubita, R., additional, Andronesi, A., additional, Bobeica, R., additional, Zilisteanu, D., additional, Rusu, E., additional, Achim, C., additional, Huerta, A., additional, Caro, J., additional, Gutierrez-Solis, E., additional, Pasquariello, A., additional, Pasquariello, G., additional, Innocenti, M., additional, Grassi, G., additional, Egidi, M. F., additional, Ozturk, O., additional, Yildiz, A., additional, Gul, C. B., additional, Dilek, K., additional, Tylicki, L., additional, Jakubowska, A., additional, Weber, E., additional, Lizakowski, S., additional, Swietlik, D., additional, Rutkowski, B., additional, Postorino, A., additional, Costa, S., additional, Cristadoro, S., additional, Magazzu, G., additional, Bellinghieri, G., additional, Savica, V., additional, Buemi, M., additional, Santoro, D., additional, Lu, Y., additional, Shen, P., additional, Li, X., additional, Xu, Y., additional, Pan, X., additional, Wang, W., additional, Chen, X., additional, Zhang, W., additional, Ren, H., additional, Chen, N., additional, Mitic, B. P., additional, Cvetkovic, T., additional, Vlahovic, P., additional, Velickovic Radovanovic, R., additional, Stefanovic, V., additional, Kostic, S., additional, Djordjevic, V., additional, Ao, Q., additional, Ma, Q., additional, Cheng, Q., additional, Wang, X., additional, Liu, S., additional, Zhang, R., additional, Ozturk, S., additional, Ozmen, S., additional, Akin, D., additional, Danis, R., additional, Yilmaz, M., additional, Hajri, S., additional, Barbouche, S., additional, Okpa, H., additional, Oviasu, E., additional, Ojogwu, L., additional, Fotouhi, N., additional, Ghaffari, A., additional, Hamzavi, F., additional, Nasri, H., additional, Ardalan, M., additional, Stott, A., additional, Ullah, A., additional, Anijeet, H., additional, Ahmed, S., additional, Kohli, H. S., additional, Rajachandran, R., additional, Rathi, M., additional, Jha, V., additional, Sakhuja, V., additional, Yenigun, E., additional, Dede, F., additional, Turgut, D., additional, Koc, E., additional, Akoglu, H., additional, Piskinpasa, S., additional, Ozturk, R., additional, Odabas, A., additional, Bajcsi, D., additional, Abraham, G., additional, Kemeny, E., additional, Sonkodi, S., additional, Legrady, P., additional, Letoha, A., additional, Constantinou, K., additional, Ondrik, Z., additional, Ivanyi, B., additional, Lucisano, G., additional, Comi, N., additional, Cianfrone, P., additional, Summaria, C., additional, Piraina, V., additional, Talarico, R., additional, Camastra, C., additional, Fuiano, G., additional, Proletov, I., additional, Saganova, E., additional, Galkina, O., additional, Bogdanova, E., additional, Zubina, I., additional, Sipovskii, V., additional, Smirnov, A., additional, Bailly, E., additional, Pierre, D., additional, Kerdraon, R., additional, Grezard, O., additional, Gnappi, E., additional, Delsante, M., additional, Galetti, M., additional, Maggiore, U., additional, Manenti, L., additional, Hasan, M. J., additional, Muqueet, M. A., additional, Mostafi, M., additional, Chowdhury, I., additional, Haque, W., additional, Khan, T., additional, Kang, Y.-J., additional, Bae, E. J., additional, Cho, H. S., additional, Chang, S.-H., additional, Park, D. J., additional, Xu, G., additional, Lin, H., additional, Hu, Z., additional, Yu, X., additional, Xing, C., additional, Mei, C., additional, Zuo, L., additional, Ni, Z., additional, Ding, X., additional, Li, D., additional, Zhang, Q., additional, Feng, X., additional, and Lin, L., additional
- Published
- 2013
- Full Text
- View/download PDF
10. Protective activity of α-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis
- Author
-
Russo, E., primary, Scicchitano, F., additional, Citraro, R., additional, Aiello, R., additional, Camastra, C., additional, Mainardi, P., additional, Chimirri, S., additional, Perucca, E., additional, Donato, G., additional, and De Sarro, G., additional
- Published
- 2012
- Full Text
- View/download PDF
11. OC.07.3 ENDOSCOPIC DILATION OF CROHN'S DISEASE (CD) STRICTURES: RESULTS OF SCHEDULED OF RETREATMENT
- Author
-
Andreoli, A., primary, Annunziata, M., additional, Lecca, P.G., additional, Cosintino, R., additional, Meddi, P., additional, Camastra, C., additional, and Tesi, A., additional
- Published
- 2010
- Full Text
- View/download PDF
12. Polymorphonuclear leukocyte-derived o2-reactive species activate platelets in human whole blood
- Author
-
Pratico, D, Iuliano, Luigi, Alessandri, Cesare, Camastra, C, and Violi, Francesco
- Subjects
platelet aggregation, thrombosis - Published
- 1993
13. Rilievo notturno dei valori pressori ed effetto della riduzione del sodio nella dieta
- Author
-
Germano', Giuseppe Italo Walter, Caparra, A., LEONETTI LUPARINI, R., Giarrizzo, C., Ferri, C., Camastra, C., Coia, F., Santucci, A., and Balsano, F.
- Published
- 1991
14. Utilità del rilievo contemporaneodell'elettrocardiograma e della pressione arteriosa per 24 ore
- Author
-
Caparra, A., Pecchioli, V., Germano', U., Camastra, C., Coia, F., Germano', Giuseppe Italo Walter, and Santucci, A.
- Published
- 1991
15. Increased thromboxane metabolites excretion in liver cirrhosis.
- Author
-
Davi, G, Ferro, D, Basili, S, Iuliano, L, Camastra, C, Giammarresi, C, Santarone, S, Rocca, Bianca, Landolfi, Raffaele, Santarone,S, Rocca, Bianca (ORCID:0000-0001-8304-6423), Landolfi, Raffaele (ORCID:0000-0002-7913-8576), Davi, G, Ferro, D, Basili, S, Iuliano, L, Camastra, C, Giammarresi, C, Santarone, S, Rocca, Bianca, Landolfi, Raffaele, Santarone,S, Rocca, Bianca (ORCID:0000-0001-8304-6423), and Landolfi, Raffaele (ORCID:0000-0002-7913-8576)
- Abstract
An augmented systemic production of thromboxane (TX) A2, as assessed by urinary excretion of the thromboxane metabolites, has been described in severe liver cirrhosis. However, the significance of this finding remains unclear since in liver cirrhosis a number of phenomena i.e. altered hepatic TXA2 metabolism, increased intrasplenic platelet destruction, may affect TXA2 entry into systemic circulation as well as its metabolism. In order to further clarify this, we measured both major enzymatic metabolites of TXB2 in the urine of 44 patients affected by liver cirrhosis, subdivided in three classes on the basis of Child-Pugh criteria. Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were assayed with previously validated RIA techniques. The urinary excretion rate of 11-dehydro-TXB2 was significantly (p = 0.0001) increased in the cirrhotic patients (673.5 pg/mg cr, median) in comparison with the controls (275 pg/mg cr, median) but no significant difference could be demonstrated among the excretion rates of the three patient subgroups. The excretion rate of 2,3 dinor-TXB2 was also significantly (p = 0.0001) increased in the patients (824 pg/mg cr, median) in comparison with controls (175 pg/mg cr, median), with a significant (p < 0.05) increase from class A (381 pg/mg cr) to class C (1337 pg/mg cr). The sum of the two enzymatic metabolites was significantly (p = 0.0001 ) increased in the cirrhotic patients in comparison to controls, with a progressive increase from class A (1003 pg/mg cr, median) to class C (2240 pg/mg cr, median). The urinary excretion of 2,3 dinor-TXB2 was significantly (p = 0.008) related to plasma prothrombin fragment 1+2 (F1+2). This study provides further evidence of increased thromboxane biosynthesis in liver cirrhosis. Moreover, we demonstrate intraliver shift of thromboxane metabolic disposition, due to progressive liver decompensation, because only the fraction undergoing beta-oxidation to 2,3-dinor-TXB2 was progressively increased with the degree of
- Published
- 1998
16. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole
- Author
-
Iuliano, L., primary, Colavita, A.R., additional, Camastra, C., additional, Bello, V., additional, Quintarelli, C., additional, Alessandroni, M., additional, Piovella, F., additional, and Violi, F., additional
- Published
- 1996
- Full Text
- View/download PDF
17. Polymorphonuclear leukocyte-derived O2-reactive species activate primed platelets in human whole blood
- Author
-
Pratico, D., primary, Iuliano, L., additional, Alessandri, C., additional, Camastra, C., additional, and Violi, F., additional
- Published
- 1993
- Full Text
- View/download PDF
18. Measurement of polymorfonuclear leukocytes-derived hydrogen peroxide in whole blood
- Author
-
Pratico, D., primary, Iuliano, L., additional, Leo, R., additional, Camastra, C., additional, Censi, C., additional, and Violi, F., additional
- Published
- 1993
- Full Text
- View/download PDF
19. H202 evoked calcium transient in platelets
- Author
-
Pratico, D., primary, Iuliano, L., additional, Leo, R., additional, Camastra, C., additional, Vezza, E., additional, and Violi, F., additional
- Published
- 1993
- Full Text
- View/download PDF
20. Thromboxane biosynthesis in patients with systemic lupus erythematosus
- Author
-
Davi', G., primary, Violi, F., additional, Ferro, D., additional, Valesini, G., additional, Censi, C., additional, Camastra, C., additional, and Patrono, C., additional
- Published
- 1993
- Full Text
- View/download PDF
21. A messanger-like function of oxygen free radicals? A positive feedback signal given by OH° “cripto”-OH° in the platelet activation process
- Author
-
Iuliano, L., primary, Pedersen, J.Z., additional, Pratico, D., additional, Camastra, C., additional, Censi, C., additional, and Violi, F., additional
- Published
- 1993
- Full Text
- View/download PDF
22. Abnormalities of primary hemostasis in patients with liver cirrhosis
- Author
-
Leo, R., primary, Alessandri, C., additional, Vezza, E., additional, Basili, S., additional, Camastra, C., additional, Alessandroni, M., additional, and Violi, F., additional
- Published
- 1993
- Full Text
- View/download PDF
23. Protection of low density lipoprotein oxidation by the antioxidant agent IRFI005, a new synthetic hydrophilic vitamin E analogue - inhibiting effects of water-soluble antioxidants on phospholipids of different charge types
- Author
-
Iuliano, L., Pedersen, J.Z., Camastra, C., Bello, V., Ceccarelli, S., and Violi, F.
- Published
- 1999
- Full Text
- View/download PDF
24. Enhanced Lipid Peroxidation in Hepatic Cirrhosis
- Author
-
Pratico, D., Iuliano, L., Stefania Basili, Ferro, D., Camastra, C., Cordova, C., Fitzgerald, G. A., and Violi, F.
- Subjects
Adult ,Male ,liver cirrhosis ,Dinoprost ,Antioxidants ,8-epi prostaglandin f-2 alpha ,8-epi prostaglandin f2α ,alcoholic liver-disease ,association ,e-deficient rats ,factor vii ,fibrogenesis ,free-radicals ,humans ,noncyclooxygenase ,prostaglandin ,stress in-vivo ,tocopherol ,vitamin e ,Aged ,F2-Isoprostanes ,Middle Aged ,Case-Control Studies ,Female ,Lipid Peroxidation - Abstract
Lipid peroxidation is thought to play a role in the evolution of liver damage, based on evidence in experimental models. However, evidence that lipid peroxidation occurs in patients with liver disease remains to be provided. We addressed the hypothesis by measuring levels of 8-epi Prostaglandin F2 alpha a bioactive prostaglandin isomer produced by free radical catalyzed peroxidation of arachidonic acid, in patients with liver cirrhosis.In 42 patients with hepatic cirrhosis 8-epi Prostaglandin F2 alpha, factor VII activity, endotoxemia, carotenoids and alpha-tocopherol were measured. In 10 patients 8-epi Prostaglandin F2 alpha was also measured before and 30 days after 300 mg b.i.d. vitamin E administration.Cirrhotic patients had significant higher 8-epi Prostaglandin F2 alpha, excretion than controls [median (range): 199.2 (60.0-812) vs 85.9 (55.6-160.0) pg/mg creatinine, p0.0001]. Patients with urinary 8-epi Prostaglandin F2 alpha above the range in controls were more likely to have moderate or severe than mild liver failure (p0.004). They also had lower factor VII activity (62 +/- 19 vs 74 +/- 15%, P0.02) than patients with normal levels of the isoprostane. Urinary excretion of 8-epi Prostaglandin F2 alpha correlated directly with endotoxemia (Rho = 0.56, p0.0002) and inversely with factor VII (Rho = -0.39, p0.02). Cirrhotic patients given vitamin E showed a significant decrease of urinary 8-epi Prostaglandin F 2 alpha [median (range): 342.5 (170 - 812) vs 292.5 (142-562) pg/mg creatinine, p0.04].This study demonstrated that lipid peroxidation is increased in vivo in patients with cirrhosis and suggests that oxidant stress might contribute to the deterioration of liver disease.
25. Increased oxidant stress in liver cirrhosis
- Author
-
Pratico, D., Basili, S., Cordova, C., Luigi Iuliano, Ferro, D., Camastra, C., and Violi, F.
26. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
- Author
-
Annalisa Di Cello, Carmela De Marco, Anna Di Vito, Cirino Botta, Tullio Barni, Nicoletta Staropoli, Ivan Presta, Antonia Rizzuto, Caterina Camastra, Chiara Mignogna, Pierfrancesco Tassone, Renato Franco, Giuseppe Donato, Angela Salvino, Natalia Malara, Pierosandro Tagliaferri, Michele Morelli, Mignogna, Chiara, Staropoli, Nicoletta, Botta, Cirino, De Marco, Carmela, Rizzuto, Antonia, Morelli, Michele, Di Cello, Annalisa, Franco, Renato, Camastra, Caterina, Presta, Ivan, Malara, Natalia, Salvino, Angela, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Barni, Tullio, Donato, Giuseppe, Di Vito, Anna, Mignogna C., Staropoli N., Botta C., De Marco C., Rizzuto A., Morelli M., Di Cello A., Franco R., Camastra C., Presta I., Malara N., Salvino A., Tassone P., Tagliaferri P., Barni T., Donato G., and Di Vito A.
- Subjects
0301 basic medicine ,Oncology ,Adult ,medicine.medical_specialty ,Bevacizumab ,endocrine system diseases ,Prognosi ,medicine.medical_treatment ,High-grade serous ovarian carcinoma (HGSOC) ,Gene Expression ,Antineoplastic Agents ,Kaplan-Meier Estimate ,Brief Communication ,03 medical and health sciences ,0302 clinical medicine ,Ovarian carcinoma ,Internal medicine ,Obstetrics and Gynaecology ,Medicine ,Humans ,Platinum ,Aged ,Aurora Kinase A ,Neoplasm Staging ,Gynecology ,Aged, 80 and over ,Ovarian Neoplasms ,Chemotherapy ,AURKA ,business.industry ,Obstetrics and Gynecology ,Retrospective cohort study ,Middle Aged ,Prognosis ,Immunohistochemistry ,female genital diseases and pregnancy complications ,Cystadenocarcinoma, Serous ,Clinical trial ,Serous fluid ,030104 developmental biology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Female ,Personalized medicine ,Therapy ,business ,medicine.drug - Abstract
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p
- Full Text
- View/download PDF
27. Development and Implementation of an Innovative Framework for Automated Radiomics Analysis in Neuroimaging.
- Author
-
Camastra C, Pasini G, Stefano A, Russo G, Vescio B, Bini F, Marinozzi F, and Augimeri A
- Abstract
Radiomics represents an innovative approach to medical image analysis, enabling comprehensive quantitative evaluation of radiological images through advanced image processing and Machine or Deep Learning algorithms. This technique uncovers intricate data patterns beyond human visual detection. Traditionally, executing a radiomic pipeline involves multiple standardized phases across several software platforms. This could represent a limit that was overcome thanks to the development of the matRadiomics application. MatRadiomics, a freely available, IBSI-compliant tool, features its intuitive Graphical User Interface (GUI), facilitating the entire radiomics workflow from DICOM image importation to segmentation, feature selection and extraction, and Machine Learning model construction. In this project, an extension of matRadiomics was developed to support the importation of brain MRI images and segmentations in NIfTI format, thus extending its applicability to neuroimaging. This enhancement allows for the seamless execution of radiomic pipelines within matRadiomics, offering substantial advantages to the realm of neuroimaging.
- Published
- 2024
- Full Text
- View/download PDF
28. Corpus callosum damage in PSP and unsteady PD patients: A multimodal MRI study.
- Author
-
Eugenia Caligiuri M, Quattrone A, Giovanna Bianco M, Riccardo Aquila V, Celeste Bonacci M, Calomino C, Camastra C, Buonocore J, Augimeri A, Morelli M, and Quattrone A
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Postural Balance physiology, Diffusion Tensor Imaging methods, Corpus Callosum diagnostic imaging, Corpus Callosum pathology, Supranuclear Palsy, Progressive diagnostic imaging, Supranuclear Palsy, Progressive pathology, Parkinson Disease diagnostic imaging, Parkinson Disease pathology, Magnetic Resonance Imaging methods, Multimodal Imaging
- Abstract
Introduction: Postural instability (PI) is a common disabling symptom in Parkinson's disease (PD) patients, but the brain alterations underlying this sign are not fully understood yet. This study aimed to investigate the association between PI and callosal damage in PD and progressive supranuclear palsy (PSP) patients, using multimodal MR imaging., Methods: One-hundred and two PD patients stratified according to the presence/absence of PI (PD-steady N=58; PD-unsteady N=44), 69 PSP patients, and 38 healthy controls (HC) underwent structural and diffusion 3T brain MRI. Thickness, fractional anisotropy (FA) and mean diffusivity (MD) were calculated over 50 equidistant points covering the whole midsagittal profile of the corpus callosum (CC) and compared among groups. Associations between imaging metrics and postural instability score were investigated using linear regression., Results: Both PSP and PD-unsteady patient groups showed CC involvement in comparison with HC, while no difference was found between PD-steady patients and controls. The CC damage was more severe and widespread in PSP than in PD patients. The CC genu was the regions most damaged in PD-unsteady patients compared with PD-steady patients, showing significant microstructural alterations of MD and FA metrics. Linear regression analysis pointed at the MD in the CC genu as the main contributor to PI among the considered MRI metrics., Conclusion: This study identified callosal microstructural alterations associated with PI in unsteady PD and PSP patients, which provide new insights on PI pathophysiology and might serve as imaging biomarkers for assessing postural instability progression and treatment response., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease.
- Author
-
Cantoro L, Monterubbianesi R, Falasco G, Camastra C, Pantanella P, Allocca M, Cosintino R, Faggiani R, Danese S, and Fiorino G
- Abstract
Delayed diagnosis is a challenge in the management of inflammatory bowel disease (IBD). Several studies show a significant association between diagnostic delay and disease progression to complications and surgery, especially in Crohn's disease (CD). What risk factors are associated with diagnostic delay in IBD remains unclear. In order to reduce diagnostic delay, the Red Flags Index has been developed and validated. The combination of the Red Flags Index score and non-invasive biomarkers such as fecal calprotectin seems to be highly accurate in screening patients with underlying IBD to be referred for further diagnostic workup and eventual early effective treatment strategies. Our literature review aims to obtain a comprehensive overview of the impacts of diagnostic delay in IBD on the potential risk factors associated with IBD, how diagnostic tools may be effective in reducing diagnostic delay, and future perspectives in this field.
- Published
- 2023
- Full Text
- View/download PDF
30. Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.
- Author
-
Scribano ML, Aratari A, Neri B, Bezzio C, Balestrieri P, Baccolini V, Falasco G, Camastra C, Pantanella P, Monterubbianesi R, Tullio A, Saibeni S, Papi C, Biancone L, Cosintino R, and Faggiani R
- Abstract
Background: The effectiveness of ustekinumab in patients with refractory Crohn's disease (CD) has been investigated in several real-world studies. However, very few data concerning the real-life experience in Italy have been reported. Therefore, this study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory CD., Methods: All patients who had started on ustekinumab after failure of or intolerance to antitumour necrosis factor-α (TNF-α) treatment at five tertiary centres between November 2018 and February 2020 were retrospectively enrolled. The coprimary outcome was corticosteroid-free clinical remission, defined as a Harvey-Bradshaw Index (HBI) score of ⩽4, at weeks 26 and 52. The secondary outcomes were changes in the HBI and C-reactive protein (CRP) values at weeks 8, 26, and 52 from baseline and the normalization of CRP in patients with initially abnormal values., Results: Totally, 140 patients who had previously received at least one anti-TNF-α agent were enrolled; 40.0% received two anti-TNF-α agents and 20.0% received vedolizumab. At baseline, 108 patients (77.1%) had HBI scores of >4; of these, 56.5% and 58.3% achieved corticosteroid-free clinical remission at weeks 26 and 52, respectively. Significant decreases in HBI and CRP values were observed at weeks 8, 26, and 52 in the entire study cohort (all p < 0.0001). The CRP values were normalized in 34.9%, 37.8%, and 49.3% of the patients by weeks 8, 26, and 52, respectively. The baseline HBI score of ⩾8 was a negative predictor of corticosteroid-free clinical remission at week 52 (odds ratio: 0.21, 95% confidence interval: 0.08-0.56, p = 0.002). The probability of remaining on ustekinumab after 52 weeks was 92.1%. Eleven (7.9%) patients discontinued ustekinumab (three for adverse events)., Conclusion: Our study findings confirm the effectiveness and safety of ustekinumab in patients with CD after failure of or intolerance to anti-TNF-α therapy., Competing Interests: Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MLS: advisory board and/or lecture fees from AbbVie, Celltrion, Janssen, Pfizer, and Takeda. CB: lecture fees from Takeda, AbbVie, and Janssen. SS: advisory board and lecture fees from Arena, Gilead, Janssen, Takeda, and AbbVie. CP: consultancy fees and/or educational grants from AbbVie, MSD, Takeda, Pfizer, Janssen-Cilag, Chiesi, Sofar, Ferring, and Zambon. LB: speaker fees from Ferring, AbbVie, Janssen, and Zambon. The other authors declare no conflict of interest., (© The Author(s), 2022.)
- Published
- 2022
- Full Text
- View/download PDF
31. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
- Author
-
Raffone A, Travaglino A, Gabrielli O, Micheli M, Zuccalà V, Bitonti G, Camastra C, Gargiulo V, Insabato L, and Zullo F
- Subjects
- Aged, Biomarkers, Tumor genetics, DNA Polymerase II metabolism, Endometrial Neoplasms pathology, Female, Genes, p53, Humans, Middle Aged, Mutation, PTEN Phosphohydrolase genetics, Phenotype, Poly-ADP-Ribose Binding Proteins metabolism, Prognosis, Risk Assessment, DNA Polymerase II genetics, Endometrial Neoplasms classification, Endometrial Neoplasms genetics, Poly-ADP-Ribose Binding Proteins genetics, Tumor Suppressor Protein p53 genetics
- Abstract
Background: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking., Objective: To provide a clinical characterization of the ProMisE groups of EC., Methods: A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated., Results: Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were: in the MMR-d group, age = 66.5 ± 0.6; BMI = 30.6 ± 1.2; stage I = 72.6%; adjuvant treatment = 47.3%; in the POLE-mt group, age = 58.6 ± 2.7; BMI = 27.2 ± 0.9; stage I = 93.7%; adjuvant treatment = 53.6%; in the p53-wt group, age = 64.2 ± 1.9; BMI = 32.3 ± 1.4; stage I = 80.5%; adjuvant treatment = 45.3%; in the p53-abn group, age = 71.1 ± 0.5; BMI = 29.1 ± 0.5; stage I = 50.8%; adjuvant treatment = 64.4%., Conclusion: The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features.
- Published
- 2021
- Full Text
- View/download PDF
32. Deregulation of SGK1 in Ulcerative Colitis: A Paradoxical Relationship Between Immune Cells and Colonic Epithelial Cells.
- Author
-
Spagnuolo R, Dattilo V, D'Antona L, Cosco C, Tallerico R, Ventura V, Conforti F, Camastra C, Mancina RM, Catalogna G, Cosco V, Iuliano R, Carbone E, Perrotti N, Amato R, and Doldo P
- Subjects
- Cell Line, Colon cytology, Colon pathology, Down-Regulation, Humans, Interleukin-13 metabolism, Interleukin-17 metabolism, Intestinal Mucosa cytology, Leukocytes, Mononuclear, RNA, Messenger metabolism, Th17 Cells immunology, CD4-Positive T-Lymphocytes metabolism, Colitis, Ulcerative genetics, Colitis, Ulcerative immunology, Epithelial Cells metabolism, Immediate-Early Proteins metabolism, Protein Serine-Threonine Kinases metabolism
- Abstract
Background: Inflammatory bowel disease (IBD) is due to the interaction of genetic and environmental factors that trigger an unbalanced immune response ultimately resulting in the peculiar inflammatory reaction. Experimental models of IBD point to a role of T-cell-derived cytokines (Th17) and to SGK1 as mediator of the Th17 switch. We hypothesize that SGK1, a salt inducible kinase, directs lymphocytic behavior and tissue damage., Methods: Eleven controls and 32 ulcerative colitis (UC) patients were randomized according to endoscopic Mayo score. Mucosal biopsies from different intestinal tracts were analyzed by immunohistochemistry and quantitative real-time polymerase chain reaction to check the expression of disease markers including SGK1. Peripheral blood mononuclear cells (PBMCs) from patients and controls were analyzed by fluorescence-activated cell sorting. Finally, an in vitro cell model was developed to test the hypothesis., Results: SGK1 mRNA and protein expression in lesional areas of UC patients were lower than in normal peri-lesional areas of the same patients and in normal tissues of healthy controls. SGK1 expression was increased in PBMCs from UC patients, particularly in the CD4+ cell population, enriched in Th17 cells. IL17/IL13 was increased in patients and correlated with SGK1 expression. Genetically engineered Jurkat cells confirmed the effect of SGK1 overexpression on viability of RKO cells., Conclusions: These observations suggest a pathogenic mechanism whereby SGK1 overexpression in CD4+ T cells induces the secretion of the inflammatory cytokines IL17 and IL13, which downregulate the expression of SGK1 in target tissues. Our data suggest a novel hypothesis in the pathogenesis of UC, integrating colonic epithelial cells and lymphocytes., (© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2018
- Full Text
- View/download PDF
33. Hindlimb Ischemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery.
- Author
-
Sorrentino S, Iaconetti C, De Rosa S, Polimeni A, Sabatino J, Gareri C, Passafaro F, Mancuso T, Tammè L, Mignogna C, Camastra C, Esposito G, Curcio A, Torella D, and Indolfi C
- Subjects
- Animals, Disease Models, Animal, MicroRNAs metabolism, Nitric Oxide metabolism, Rats, rho-Specific Guanine Nucleotide Dissociation Inhibitors metabolism, Carotid Arteries pathology, Endothelial Cells pathology, Hindlimb pathology, Ischemia pathology, Neointima
- Abstract
Peripheral ischemia is associated with higher degree of endothelial dysfunction and a worse prognosis after percutaneous coronary interventions (PCI). However, the role of peripheral ischemia on vascular remodeling in remote districts remains poorly understood. Here we show that the presence of hindlimb ischemia significantly enhances neointima formation and impairs endothelial recovery in balloon-injured carotid arteries. Endothelial-derived microRNAs are involved in the modulation of these processes. Indeed, endothelial miR-16 is remarkably upregulated after vascular injury in the presences of hindlimb ischemia and exerts a negative effect on endothelial repair through the inhibition of RhoGDIα and nitric oxide (NO) production. We showed that the repression of RhoGDIα by means of miR-16 induces RhoA, with consequent reduction of NO bioavailability. Thus, hindlimb ischemia affects negative carotid remodeling increasing neointima formation after injury, while systemic antagonizzation of miR-16 is able to prevent these negative effects.
- Published
- 2018
- Full Text
- View/download PDF
34. Inflammation and macrophage polarization in cutaneous melanoma: Histopathological and immunohistochemical study.
- Author
-
Scali E, Mignogna C, Di Vito A, Presta I, Camastra C, Donato G, and Bottoni U
- Subjects
- Adult, Aged, Disease Progression, Female, Humans, Immunotherapy methods, Lymphocytes pathology, Macrophage Activation physiology, Male, Middle Aged, Prognosis, Skin Neoplasms, Melanoma, Cutaneous Malignant, Inflammation pathology, Macrophages pathology, Melanoma pathology
- Abstract
Tumor-associated macrophages (TAMs) are considered to affect tumor growth and progression. Macrophages can be classified into two states of polarized activation, namely classically activated M1 macrophages and alternatively activated M2 macrophages. The dynamic balance between TAMs and tumor cells has an important impact on tumor homeostasis and progression. The aim of this study was to characterize the phenotype of TAMs present in different subtypes of superficial spreading cutaneous melanoma and their relationship with the lymphocytic infiltrate in order to identify new histopathological tools for melanoma prognosis and suitable targets for melanoma therapy. We selected four groups of patients with malignant melanoma in order to analyze the profile of polarized macrophage activation using immunohistochemical methods. Histopathological analysis showed that the macrophage polarization state appears to be more related to the lymphocytic infiltrate than to the thickness of the lesions. Further studies are necessary to increase understanding of the immunopathological dynamic of melanoma that may be modulated by future targeted immunotherapies., (© The Author(s) 2016.)
- Published
- 2016
- Full Text
- View/download PDF
35. Circulating non-hematological cells during cardiopulmonary bypass: new findings in cardiac surgery procedures.
- Author
-
Santise G, Marinaro C, Maselli D, Dominici C, Di Vito A, Donato G, Camastra C, Zeppa P, Barni T, Rizzuto A, Viglietto G, and Mignogna C
- Subjects
- Aged, Blood Coagulation Tests, Calbindin 2 analysis, Cardiopulmonary Bypass adverse effects, Coronary Artery Bypass adverse effects, Coronary Artery Bypass methods, Epithelial Cells pathology, Female, Humans, Immunomagnetic Separation, Keratins analysis, Male, Middle Aged, Prospective Studies, Thrombelastography, Blood Coagulation, Cardiopulmonary Bypass methods, Epithelial Cells cytology
- Abstract
Background: Several factors have been historically advocated to explain the coagulative and inflammatory disorders following cardiopulmonary bypass (CPB). In this paper, we describe the presence of circulating non-hematological cells, introduced within the bloodstream during CPB. We defined the origin of the cells and tested their impact on coagulation., Methods: We collected peripheral arterial blood samples in twenty consecutive coronary artery bypass graft cases at four different surgical moments and assessed the presence and nature of circulating cells with the use of the CELLSEARCH® Test, immunocytochemistry and immunofluorescence, evaluating the expression of cytokeratin and calretinin. The effect of the circulating non-hematological cells on coagulation was tested in vitro, using the ROTEM assay., Results: A mean of 263.85 ± 57.5 (median 258.5) cells were present in the samples following the suction of blood from the surgical field while all the other samples were negative (zero cells) (p<0.00001). Immunologic tests confirmed the mesothelial origin of the cells. The ROTEM® assay of the blood samples contaminated by the mesothelial cells presented longer clotting times (53.4 ± 8.2 secs 48.3 ± 8.9 sec, p=0.05), longer clot formation times (137.1 ± 31.5 sec vs 111.9 ± 25.2 sec, p=0.009), smaller alfa angle amplitudes (66.7 ± 9.1° vs 71.1 ± 5.1°, p=0.04) and maximum clot firmness times (59.0 ± 5.4 sec vs 61.9 ±4.6 sec, p=0.004) than the controls., Conclusion: The presence of circulating non-hematological cells during CPB with a mesothelial immunophenotype alters in vitro coagulation assays. This finding can help to further understand the pathophysiology of CPB., (© The Author(s) 2016.)
- Published
- 2016
- Full Text
- View/download PDF
36. A case of intravascular large B cell lymphoma: New clinical and immunohistochemical findings.
- Author
-
Mansueto G, Di Vito A, Belluomo C, Murino P, Natella V, Camastra C, Presta I, Malara N, de Rosa G, Donato G, and Mignogna C
- Subjects
- Antigens, CD20 metabolism, Brain blood supply, Female, Galectin 3 metabolism, Humans, Immunohistochemistry, Lymphoma, B-Cell diagnosis, Middle Aged, Proto-Oncogene Proteins c-bcl-2 metabolism, Proto-Oncogene Proteins c-myc, Brain metabolism, Brain pathology, Lymphoma, B-Cell metabolism, Lymphoma, B-Cell pathology
- Abstract
Intravascular large B cell lymphoma (IVLBCL) is a rare extranodal non-Hodgkin lymphoma characterized by proliferation of malignant cells within the lumen of small vessels, with a predilection for the CNS and the skin. IVLBCL clinical course is highly aggressive, clinical signs and symptoms are not specific and may consist of neurological and cognitive impairment, fever of unknown origin and cutaneous lesions, lacking of a typical neuroimaging pattern. For all these reasons the diagnosis is commonly missed and the exitus is frequent, therefore post mortem evaluation is necessary to clarify the clinical history. We present a case of IVLBCL in a 62-year-old woman with unusual symptomatology, mimicking a vascular, multi-infarctual cerebropathy. Hachinski Ischemic Score was 7 suggesting a vascular dementia. Autopsy was unable to define the nature of the disease. Immunohistochemical analysis for cluster of differentiation 20 (CD20) revealed the ubiquitous presence of malignant lymphoid B-cells into the vessel of all organs analyzed, allowing the definitive diagnosis of IVLBCL. The atypical cells expressed high levels of anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Galectin-3, and showed cellular myelocytomatosis (c-Myc) staining in <50% of tumor nuclei. Conversely, cells were immunonegative for multiple myeloma-1 (MUM1), CD3, CD44, CD30, CD34 and CD133. Fluorescent in situ hybridization analysis for MYC rearrangements was negative. The high expression of Galectin-3 provides new insights in the understanding of molecular pathogenesis of IVLBCL; indeed, such a finding represents a prognostic factor for other types of lymphoma and should, in the same way, be taken into account in IVLBCL., (© 2016 Japanese Society of Neuropathology.)
- Published
- 2016
- Full Text
- View/download PDF
37. A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature.
- Author
-
Mignogna C, Signorelli F, Vismara MF, Zeppa P, Camastra C, Barni T, Donato G, and Di Vito A
- Subjects
- Adult, Aged, Antigens, CD metabolism, Antigens, Differentiation, Myelomonocytic metabolism, Brain Neoplasms metabolism, Female, Glioblastoma metabolism, Humans, Immunohistochemistry, Macrophages metabolism, Male, Middle Aged, Receptors, Cell Surface metabolism, Retrospective Studies, Tumor Microenvironment physiology, Brain Neoplasms pathology, Cell Polarity physiology, Glioblastoma pathology, Macrophages pathology
- Abstract
The survival rate in glioblastoma multiforme patients has scarcely improved in the last decades; however, many new therapeutic strategies have been theorized or developed for these neoplasias. Recently, the inverse correlation observed between patient prognosis and tumor-associated macrophages (TAMs) density in solid tumors has encouraged the development of anti-tumor strategies aiming to target TAMs. As expected, TAMs polarization is influenced by both macrophage localization and tumor microenvironment signals, resulting in a more complex scenario than the simple M1/M2 activation status. Macrophage polarization in glioblastoma has not yet been fully elucidated, and most results have been obtained in experimental non-human settings, with some apparent contradiction. The authors performed a histopathological and immunohistochemical study of 37 cases of glioblastoma in order to characterize the M1 and M2 macrophage populations within TAMs. A high prevalence of CD163+ M2-polarized macrophages was detected in this cohort, whereas iNOS+ macrophages were rarely found. The down-regulation of CD68 expression in microglia/macrophage infiltrating glioblastomas is also reported for the first time. Such a finding is associated with a specific location of TAMs within the lesion, as confirmed by the fact that CD68 staining was lower than CD163, mainly in perivascular areas. The authors discuss the recent literature about the global scenario of macrophage plasticity and polarization in glioblastoma, and suggest some pivotal points for therapeutic applications., (Copyright © 2016 Elsevier GmbH. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
38. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
- Author
-
Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, and Di Vito A
- Subjects
- Adult, Aged, Aged, 80 and over, Aurora Kinase A metabolism, Cystadenocarcinoma, Serous genetics, Cystadenocarcinoma, Serous mortality, Cystadenocarcinoma, Serous pathology, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Middle Aged, Neoplasm Staging, Ovarian Neoplasms pathology, Prognosis, Antineoplastic Agents pharmacology, Aurora Kinase A genetics, Drug Resistance, Neoplasm genetics, Gene Expression, Ovarian Neoplasms genetics, Ovarian Neoplasms mortality, Platinum pharmacology
- Abstract
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10-0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment.
- Published
- 2016
- Full Text
- View/download PDF
39. AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer.
- Author
-
Malanga D, Belmonte S, Colelli F, Scarfò M, De Marco C, Oliveira DM, Mirante T, Camastra C, Gagliardi M, Rizzuto A, Mignogna C, Paciello O, Papparella S, Fagman H, and Viglietto G
- Subjects
- Animals, Bronchi drug effects, Bronchi pathology, Carcinogenesis drug effects, Carcinogenesis genetics, Cell Transformation, Neoplastic drug effects, Epithelial Cells drug effects, Epithelial Cells pathology, Female, Humans, Hyperplasia, Lung drug effects, Lung pathology, Lung Neoplasms pathology, Mice, Mice, Transgenic, Pregnancy, Protein Structure, Tertiary, Proto-Oncogene Proteins c-akt chemistry, Urethane pharmacology, Carcinogens pharmacology, Lung Neoplasms chemically induced, Lung Neoplasms genetics, Mutation, Oncogenes genetics, Proto-Oncogene Proteins c-akt genetics
- Abstract
The hotspot AKT1E17K mutation in the pleckstrin homology domain of AKT1 occurs in approximately 0.6-2% of human lung cancers. Recently, we have demonstrated that AKT1E17K transforms immortalized human bronchial cells. Here by use of a transgenic Cre-inducible murine strain in the wild type Rosa26 (R26) locus (R26-AKT1E17K mice) we demonstrate that AKT1E17K is a bona-fide oncogene and plays a role in the development of lung cancer in vivo. In fact, we report that mutant AKT1E17K induces bronchial and/or bronchiolar hyperplastic lesions in murine lung epithelium, which progress to frank carcinoma at very low frequency, and accelerates tumor formation induced by chemical carcinogens. In conclusion, AKT1E17K induces hyperplasia of mouse lung epithelium in vivo and cooperates with urethane to induce the fully malignant phenotype.
- Published
- 2016
- Full Text
- View/download PDF
40. The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model.
- Author
-
Russo E, Follesa P, Citraro R, Camastra C, Donato A, Isola D, Constanti A, De Sarro G, and Donato G
- Subjects
- Animals, Cell Proliferation physiology, Disease Models, Animal, Electroencephalography, Epilepsy, Absence metabolism, Epilepsy, Absence pathology, Hippocampus metabolism, Immunohistochemistry, Male, Rats, Rats, Wistar, Signal Transduction physiology, Epilepsy, Absence physiopathology, Hippocampus pathology, Neural Stem Cells pathology, TOR Serine-Threonine Kinases metabolism
- Abstract
Hyperactivation of mammalian target of rapamycin (mTOR) signaling pathway occurs after an epileptogenic insult and, its inhibition prevents the development of spontaneous seizures. We have recently demonstrated that mTOR's inhibition by rapamycin (started before seizure onset), permanently reduces the development of spontaneous absence seizures in WAG/Rij rats, an animal model of absence epilepsy; furthermore, mTOR phosphorylation was increased in adult WAG/Rij rats' cortex, but not other brain areas. However, it was not clear whether this hyperphosphorylation was a cause or a consequence of absence seizure. Here, we have addressed this issue by analyzing immunohistochemically: (1) the brain levels of total and phosphorylated mTOR in young (before seizures) and adult WAG/Rij rats; (2) the proliferation of hippocampal neuronal stem/progenitor cells assessed by BrdU analysis at different ages. WAG/Rij rats have higher levels of total mTOR in several brain areas than Wistar rats; phospho-mTOR staining is higher in young WAG/Rij rats than control and adult WAG/Rij rats. Finally, the age-related decline in hippocampal neural progenitor cell proliferation rate was slower in WAG/Rij than Wistar rats. Our results support a role for persistent mTOR activation and consequent change in hippocampal progenitor cell proliferation during the epileptogenic process leading to the development of absence seizures in WAG/Rij rats.
- Published
- 2014
- Full Text
- View/download PDF
41. The role of mast cell tryptases in cardiac myxoma: Histogenesis and development of a challenging tumor.
- Author
-
Donato G, Conforti F, Camastra C, Ammendola M, Donato A, and Renzulli A
- Abstract
A number of available studies have focused on the role of mastocytes and their angiogenic factors, such as tryptase expression, in cancer growth as a major research objective. Cardiac myxoma is a rare neoplasia and is the most common primary tumor of the heart. The cellular elements of cardiac myxoma have an endothelial phenotype; however, its histogenesis remains unclear. Currently, no available studies have correlated the pathological characteristics of cardiac myxomas, such as cell differentiation and vascularization, with the angiogenic factors of mast cells. The aim of the present study was to investigate the role of mast cell tryptases on the development of cardiac myxomas and examine the histogenesis of tumoral cells. A series of 10 cardiac myxomas were examined by immunohistochemical analysis for the presence of tryptase-positive mast cells. Statistical analysis of our data demonstrated that angiogenesis and the development of pseudovascular structures were correlated with the number of tryptase-positive mast cells. Therefore, we hypothesize that cardiac myxoma cells are endothelial precursors which are able to generate mature vascular structures. Further morphological and immunophenotypic analyses of tumoral cells may corroborate such a hypothesis.
- Published
- 2014
- Full Text
- View/download PDF
42. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy.
- Author
-
Russo E, Citraro R, Donato G, Camastra C, Iuliano R, Cuzzocrea S, Constanti A, and De Sarro G
- Subjects
- Animals, Anticonvulsants blood, Anticonvulsants therapeutic use, Behavior, Animal drug effects, Depression etiology, Electroencephalography, Epilepsy, Absence genetics, Feeding Behavior drug effects, Immunohistochemistry, Lipopolysaccharides pharmacology, Motor Activity drug effects, Neurosurgical Procedures, Rats, Rats, Wistar, Sirolimus blood, Sirolimus pharmacology, Sucrose pharmacology, Swimming psychology, Depression psychology, Epilepsy, Absence etiology, Epilepsy, Absence psychology, Seizures prevention & control, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Several signaling pathways are believed to be involved in the epileptogenic process that triggers the subsequent changes in the brain causing epilepsy. The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that in the brain, regulates several important physiological functions such as neuronal development and synaptic plasticity, and also seems to be involved in many pathologies, including epilepsy and psychiatric disorders. Previous work in animal models of both genetic and acquired generalized convulsive epilepsies, has suggested that modulators of the mTOR signaling pathway may have beneficial neuroprotective and antiepileptogenic effects. Here, we investigated for the first time, the effect of some treatment schedules (i.e. early chronic, sub-chronic and acute) with the specific mTOR inhibitor rapamycin, on the development of absence seizures and seizure parameters as well as depressive-like behavior in WAG/Rij rats, a genetic model of absence epilepsy, epileptogenesis and mild-depression comorbidity. In addition, we studied the possible interaction between rapamycin treatment and the effects of bacterial lipopolysaccharide (LPS) endotoxin administration, which is known to aggravate absence seizures through generation of increased neuroinflammatory responses. We found that rapamycin (early chronic treatment for 17 weeks, starting at P45) exhibited clear antiepileptogenic properties also in this animal epilepsy model; however, this effect was accompanied by unexpected prodepressant effects. Both acute and sub-chronic (7 day) treatments also had anti-absence properties, but the sub-chronic treatment produced contrasting antidepressant properties in the WAG/Rij rats that were not seen in control Wistar rats. The rapamycin/LPS co-administration studies showed that rapamycin blocked or prevented the LPS-dependent increase in absence seizures, suggesting an anti-inflammatory-like protective action. In conclusion, we have demonstrated a novel antiepileptogenic effect of rapamycin in a well-established animal model of absence epilepsy, and we suggest that this effect may be mediated by the inhibition of inflammatory processes that are developed in the brain of these specific animals during epileptogenesis and during seizures. Our experiments here suggest new insights into this intriguing field, which deserves to be further explored. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
43. New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review.
- Author
-
Perrotta I, Russo E, Camastra C, Filice G, Di Mizio G, Colosimo F, Ricci P, Tripepi S, Amorosi A, Triumbari F, and Donato G
- Subjects
- Aged, Aged, 80 and over, Aortic Valve metabolism, Aortic Valve ultrastructure, Aortic Valve Stenosis immunology, Aortic Valve Stenosis pathology, Calcinosis immunology, Calcinosis pathology, Female, Humans, Immunohistochemistry, Inflammation immunology, Inflammation metabolism, Inflammation pathology, Male, Matrix Metalloproteinase 12 metabolism, Microscopy, Electron, Transmission, Middle Aged, Osteonectin metabolism, Osteopontin metabolism, Tenascin metabolism, Aortic Valve Stenosis metabolism, Calcinosis metabolism, Elastin metabolism
- Abstract
Aims: Calcific aortic stenosis is a progressive disease characterized by massive fibrosis andmineralization of the valve leaflets. The aim of this study was to determine whether the onset of native calcific aortic stenosis is associated primarily with matrix remodelling events, and particularly with elastin degradation., Methods and Results: The immunohistochemical expression profile of matrix degradating enzymes and tenascin-C was investigated in both healthy and native calcified aortic valves. Collagen and elastic tissue were studied by light microscopy and electron microscopy. Immunophenotypic analysis of inflammatory cells was carried out by using monoclonal antibodies to macrophages, T and B lymphocytes. Immunoreactivity for tenascin-C and matrix metalloproteinase-12 (MMP-12) was associated with areas of dense mineralization, which were characterized by fibrosis, fragmentation and calcification of elastic fibres a positive reaction was also found around small islands of calcification. MMP-11 was not detected in the diseased valves. Osteopontin and osteonectin were also found at sites of mineralization. All calcified valves examined showed inflammatory cell infiltration., Conclusions: Our results demonstrate the direct involvement of MMP-12 in native aortic valve stenosis. MMP-mediated degradation of elastic fibres might contribute actively to valve mineralization by inducing calcium deposition onto fragmented elastin., (© 2011 Blackwell Publishing Limited.)
- Published
- 2011
- Full Text
- View/download PDF
44. Increased thromboxane metabolites excretion in liver cirrhosis.
- Author
-
Davì G, Ferro D, Basili S, Iuliano L, Camastra C, Giammarresi C, Santarone S, Rocca B, Landolfi R, Ciabattoni G, Cordova C, and Violi F
- Subjects
- Adult, Aged, Creatinine urine, Disease Progression, Female, Fibrin Fibrinogen Degradation Products analysis, Fibrinolysis, Humans, Liver metabolism, Liver Cirrhosis blood, Liver Cirrhosis urine, Male, Middle Aged, Oxidation-Reduction, Partial Thromboplastin Time, Peptide Fragments analysis, Prothrombin analysis, Radioimmunoassay, Blood Platelets metabolism, Liver Cirrhosis metabolism, Thromboxane A2 blood, Thromboxane B2 analogs & derivatives, Thromboxane B2 urine
- Abstract
An augmented systemic production of thromboxane (TX) A2, as assessed by urinary excretion of the thromboxane metabolites, has been described in severe liver cirrhosis. However, the significance of this finding remains unclear since in liver cirrhosis a number of phenomena i.e. altered hepatic TXA2 metabolism, increased intrasplenic platelet destruction, may affect TXA2 entry into systemic circulation as well as its metabolism. In order to further clarify this, we measured both major enzymatic metabolites of TXB2 in the urine of 44 patients affected by liver cirrhosis, subdivided in three classes on the basis of Child-Pugh criteria. Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were assayed with previously validated RIA techniques. The urinary excretion rate of 11-dehydro-TXB2 was significantly (p = 0.0001) increased in the cirrhotic patients (673.5 pg/mg cr, median) in comparison with the controls (275 pg/mg cr, median) but no significant difference could be demonstrated among the excretion rates of the three patient subgroups. The excretion rate of 2,3 dinor-TXB2 was also significantly (p = 0.0001) increased in the patients (824 pg/mg cr, median) in comparison with controls (175 pg/mg cr, median), with a significant (p < 0.05) increase from class A (381 pg/mg cr) to class C (1337 pg/mg cr). The sum of the two enzymatic metabolites was significantly (p = 0.0001 ) increased in the cirrhotic patients in comparison to controls, with a progressive increase from class A (1003 pg/mg cr, median) to class C (2240 pg/mg cr, median). The urinary excretion of 2,3 dinor-TXB2 was significantly (p = 0.008) related to plasma prothrombin fragment 1+2 (F1+2). This study provides further evidence of increased thromboxane biosynthesis in liver cirrhosis. Moreover, we demonstrate intraliver shift of thromboxane metabolic disposition, due to progressive liver decompensation, because only the fraction undergoing beta-oxidation to 2,3-dinor-TXB2 was progressively increased with the degree of liver failure. We, also, find a significant correlation between urinary excretion of 2,3-dinor-TXB2 and plasma F1+2, suggesting that clotting activation could partly account for in vivo platelet activation.
- Published
- 1998
45. Enhanced lipid peroxidation in hepatic cirrhosis.
- Author
-
Pratico D, Iuliano L, Basili S, Ferro D, Camastra C, Cordova C, FitzGerald GA, and Violi F
- Subjects
- Adult, Aged, Antioxidants metabolism, Case-Control Studies, Dinoprost analogs & derivatives, Dinoprost blood, Dinoprost urine, F2-Isoprostanes, Female, Humans, Liver Cirrhosis drug therapy, Male, Middle Aged, Vitamin E therapeutic use, Lipid Peroxidation, Liver Cirrhosis metabolism
- Abstract
Background: Lipid peroxidation is thought to play a role in the evolution of liver damage, based on evidence in experimental models. However, evidence that lipid peroxidation occurs in patients with liver disease remains to be provided. We addressed the hypothesis by measuring levels of 8-epi Prostaglandin F2 alpha a bioactive prostaglandin isomer produced by free radical catalyzed peroxidation of arachidonic acid, in patients with liver cirrhosis., Methods: In 42 patients with hepatic cirrhosis 8-epi Prostaglandin F2 alpha, factor VII activity, endotoxemia, carotenoids and alpha-tocopherol were measured. In 10 patients 8-epi Prostaglandin F2 alpha was also measured before and 30 days after 300 mg b.i.d. vitamin E administration., Results: Cirrhotic patients had significant higher 8-epi Prostaglandin F2 alpha, excretion than controls [median (range): 199.2 (60.0-812) vs 85.9 (55.6-160.0) pg/mg creatinine, p < 0.0001]. Patients with urinary 8-epi Prostaglandin F2 alpha above the range in controls were more likely to have moderate or severe than mild liver failure (p < 0.004). They also had lower factor VII activity (62 +/- 19 vs 74 +/- 15%, P < 0.02) than patients with normal levels of the isoprostane. Urinary excretion of 8-epi Prostaglandin F2 alpha correlated directly with endotoxemia (Rho = 0.56, p < 0.0002) and inversely with factor VII (Rho = -0.39, p < 0.02). Cirrhotic patients given vitamin E showed a significant decrease of urinary 8-epi Prostaglandin F 2 alpha [median (range): 342.5 (170 - 812) vs 292.5 (142-562) pg/mg creatinine, p < 0.04]., Conclusion: This study demonstrated that lipid peroxidation is increased in vivo in patients with cirrhosis and suggests that oxidant stress might contribute to the deterioration of liver disease.
- Published
- 1998
46. Preparation and biodistribution of 99m technetium labelled oxidized LDL in man.
- Author
-
Iuliano L, Signore A, Vallabajosula S, Colavita AR, Camastra C, Ronga G, Alessandri C, Sbarigia E, Fiorani P, and Violi F
- Subjects
- Adult, Arteriosclerosis metabolism, Carotid Stenosis blood, Carotid Stenosis complications, Copper Sulfate pharmacology, Feasibility Studies, Female, Humans, Hydrogen Peroxide pharmacology, Intracranial Arteriosclerosis blood, Intracranial Arteriosclerosis complications, Ischemic Attack, Transient blood, Ischemic Attack, Transient etiology, Lipid Peroxidation drug effects, Lipoproteins, LDL drug effects, Macrophages metabolism, Male, Middle Aged, Mononuclear Phagocyte System metabolism, Radionuclide Imaging, Tissue Distribution, Arteriosclerosis diagnostic imaging, Carotid Stenosis diagnostic imaging, Intracranial Arteriosclerosis diagnostic imaging, Ischemic Attack, Transient diagnostic imaging, Lipoproteins, LDL pharmacokinetics, Technetium pharmacokinetics
- Abstract
Radiolabelled autologous low density lipoprotein (LDL) has previously been used to study in vivo distribution and metabolism of native-LDL. Non-invasive imaging of atherosclerotic lesions using 99mTc-LDL was shown to be feasible in animal models and patients but the clinical utility remains to be assessed. Since recent reports suggest that oxidized LDL may play a major role in the pathogenesis of atherosclerosis, we developed a technique to oxidize autologous LDL and compared the biodistribution of oxidized-LDL with that of native-LDL in man. In addition, we evaluated the uptake in vivo of oxidized- and native-LDL by atherosclerotic plaques. LDL, obtained from human plasma was treated with various combinations of copper ions and H2O2 to induce oxidative modification by increasing the content of lipid peroxidation products and electrophoretic mobility. When LDL (0.3 mg/ml) was incubated with 100 microM Cu2+ and 500 microM H2O2 oxidation occurred rapidly within 1 h, and was labelled with 99mTc efficiently as native LDL. In vivo distribution studies revealed a faster plasma clearance of oxidized-LDL compared to native-LDL, and a higher uptake by the reticuloendothelial system. Tomographic scintigraphy of the neck in patients suffering from transient ischemic attacks, revealed accumulation of radiolabelled LDL preparations in the carotid artery affected by atherosclerotic lesions. We developed a technique to rapidly oxidize LDL using copper and H2O2. Biodistribution data demonstrate that oxidized-LDL is rapidly cleared from circulation, is taken up mostly by organs rich in macrophages, and can be detected at the level of carotid plaques.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.